Abstract Library

#4073 Comparative targeted NGS analysis between solid and liquid biopsies in GEP-NET: A pilot study

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present a broad clinical variability. Genetic profile could be a striking resource to respond to prognostic and treatment purposes. Sequencing of circulating tumor DNA (ctDNA) from liquid biopsy (LB) has been proposed as a less invasive alternative to solid biopsy (SB).

Conference:

Presenting Author:

Authors: Gagliardi I, Borges de Souza P, Martiradonna M, Rossi L, Albertelli M,

Keywords: Genetic profile, Liquid biopsy, Solid biopsy, GEP-NET, ctDNA,

#3649 Influence of pathogenic somatic mutations on the survival rates of patients with neuroendocrine tumors of the gastrointestinal tract (NET GI)

Introduction: Genomic sequencing of 40 tumors samples from patients diagnosed with NET GI was performed. Further, according to the results obtained, the survival rates of patients were evaluated.

Conference:

Presenting Author: Androsova A

Authors: Androsova A, Orlova R, Gordiev M, Ivanova A, Belyak N,

Keywords: NET, mutations, BRCA, POLE, Genomic sequencing,

#3309 Comprehensive genetic analysis of tumor suppressor genes Men1, PTEN, Rb1 and p53 in NETs in mice

Introduction: Tumor suppressor genes (TSGs) RB1, TP53 and PTEN are three of the most commonly mutated TSGs in human cancers. Multiple endocrine neoplasia type 1 (MEN1) gene is one of the most frequently mutated TSGs in human neuroendocrine tumors (NETs). Cooperative effects of genetic alterations of TSGs are frequently observed during carcinogenesis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Xu E, Vosburgh E, Wong C, Tang L, Levine A,

Keywords: neuroendocrine tumor, men1, rb, pten, p53,

#2205 Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus

Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cella C, Barberis M, Spad F, Pisa E, Laffi A,

Keywords: Everolimus, MET, RET,

#1892 Feasibility and Implication of Routine NGS Analysis in Neuroendocrine Carcinomas

Introduction: Neuroendocrine carcinomas (NECs) may arise from any organ system, exhibit various degree of differentiation and have Ki67 indices ranging from 21-100%. After first-line platin based chemotherapy, no standard treatment exists.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Knigge U, Federspiel B, Andreassen M, Kjær A, Langer S,

Keywords: neuroendocrine, neuroendocrine neoplasms, neuroendocrine carcinoma, ngs, genes, mutation, ki67, tp53, kras, braf, pik3a, pten,